ANG II-induced hypertension in the VCD mouse model of menopause is prevented by estrogen replacement during perimenopause.
Premenopausal females are resistant to the development of hypertension, and this protection is lost after the onset of menopause, resulting in a sharp increase in disease onset and severity. However, it is unknown how a fluctuating ovarian hormone environment during the transition from perimenopause to menopause impacts the onset of hypertension, and whether interventions during perimenopause prevent disease onset after menopause. A gradual transition to menopause was induced by repeated daily injections of 4-vinylcyclohexene diepoxide (VCD). ANG II (800 ng·kg(-1)·min(-1)) was infused into perimenopausal and menopausal female mice for 14 days. A separate cohort of mice received 17β-estradiol replacement during perimenopause. ANG II infusion produced significantly higher mean arterial pressure (MAP) in menopausal vs. cycling females, and 17β-estradiol replacement prevented this increase. In contrast, MAP was not significantly different when ANG II was infused into perimenopausal and cycling females, suggesting that female resistance to ANG II-induced hypertension is intact during perimenopause. ANG II infusion caused a significant glomerular hypertrophy, and hypertrophy was not impacted by hormonal status. Expression levels of aquaporin-2 (AQP2), a collecting duct protein, have been suggested to reflect blood pressure. AQP2 protein expression was significantly downregulated in the renal cortex of the ANG II-infused menopause group, where blood pressure was increased. AQP2 expression levels were restored to control levels with 17β-estradiol replacement. This study indicates that the changing hormonal environment in the VCD model of menopause impacts the severity of ANG II-induced hypertension. These data highlight the utility of the ovary-intact VCD model of menopause as a clinically relevant model to investigate the physiological mechanisms of hypertension that occur in women during the transition into menopause.
Department of Physiology, University of Arizona, Tucson, Arizona; and.
Dennis P
DP
Pollow
Department of Physiology, University of Arizona, Tucson, Arizona; and.
Melissa J
MJ
Romero-Aleshire
Department of Physiology, University of Arizona, Tucson, Arizona; and Sarver Heart Center, University of Arizona, Tucson, Arizona.
Jessica N
JN
Sanchez
Department of Physiology, University of Arizona, Tucson, Arizona; and Sarver Heart Center, University of Arizona, Tucson, Arizona.
John P
JP
Konhilas
Department of Physiology, University of Arizona, Tucson, Arizona; and Sarver Heart Center, University of Arizona, Tucson, Arizona brooksh@email.arizona.edu.
Heddwen L
HL
Brooks
D000804:Angiotensin II; D000818:Animals; D051399:Aquaporin 2 / Q000378:metabolism; D062186:Arterial Pressure / Q000187:drug effects*; D049109:Cell Proliferation / Q000187:drug effects; D053138:Cyclohexenes / Q000008:administration & dosage*; D004195:Disease Models, Animal; D004334:Drug Administration Schedule; D004958:Estradiol / Q000008:administration & dosage*; D015914:Estrogen Replacement Therapy; D005260:Female; D006973:Hypertension / Q000139:chemically induced* / Q000378:metabolism / Q000473:pathology / Q000503:physiopathology / Q000517:prevention & control*; D007274:Injections, Intraperitoneal; D007672:Kidney Cortex / Q000187:drug effects / Q000378:metabolism / Q000473:pathology; D008593:Menopause / Q000187:drug effects* / Q000378:metabolism; D008810:Mice, Inbred C57BL; D047648:Perimenopause; D012307:Risk Factors; D013997:Time Factors; D014753:Vinyl Compounds / Q000008:administration & dosage*
C496024:Aqp2 protein, mouse; D051399:Aquaporin 2; D053138:Cyclohexenes; D014753:Vinyl Compounds; D000804:Angiotensin II; D004958:Estradiol; C012606:4-vinyl-1-cyclohexene dioxide
aquaporin-2; collecting duct; estrogen; glomerular hypertrophy